A GPC2 antibody-drug conjugate is efficacious against neuroblastoma and small-cell lung cancer via binding a conformational epitope

Glypican 2 (GPC2) is a MYCN-regulated, differentially expressed cell-surface oncoprotein and target for immune-based therapies in neuroblastoma. Here, we build on GPC2’s immunotherapeutic attributes by finding that it is also a highly expressed, MYCN-driven oncoprotein on small-cell lung cancers (SC...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Cell Rep Med
Main Authors: Raman, Swetha, Buongervino, Samantha N., Lane, Maria V., Zhelev, Doncho V., Zhu, Zhongyu, Cui, Hong, Martinez, Benjamin, Martinez, Daniel, Wang, Yanping, Upton, Kristen, Patel, Khushbu, Rathi, Komal S., Navia, Carmen T., Harmon, Daniel B., Li, Yimei, Pawel, Bruce, Dimitrov, Dimiter S., Maris, John M., Julien, Jean-Philippe, Bosse, Kristopher R.
Formato: Artigo
Idioma:Inglês
Publicado em: Elsevier 2021
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC8324494/
https://ncbi.nlm.nih.gov/pubmed/34337560
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.xcrm.2021.100344
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados